Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
Department of Leukemia, University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.
Elias J
EJ
Jabbour
Timothy P
TP
Hughes
Jorge E
JE
Cortés
Hagop M
HM
Kantarjian
Andreas
A
Hochhaus
D001752:Blast Crisis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D019468:Disease Management; D018450:Disease Progression; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome
Myeloid leukemias and dysplasias; drug resistance; tyrosine kinase inhibitor